POCT CRP
[POCT CRP]
EPTIS factsheet 331665 | Last revision 2024-10-01 | URL: https://www.eptis.bam.de/pts331665 https://www.eptis.bam.de/pts331665
| PT provider | |||||||
| PT provider | Weqas Weqas | ||||||
| Based in | United Kingdom | ||||||
| Language(s) | |||||||
| Remarks | Antimicrobial resistance is a major global healthcare problem, with antibiotics for respiratory infections accounting for around 60% of all primary care prescriptions, which in turn comprise 80% of the total antibiotic burden. C-reactive protein (CRP) is a well-established marker for inflammation and infection and is increasingly used in POCT settings to help guide appropriate prescribing of antibiotics for people with lower respiratory tract infection. The programme assesses both site and method performance, including bias, within and between batch imprecision and linearity. Two liquid human serum samples are distributed bimonthly with a minimum of 12 samples distributed over the year covering a wide clinically relevant range. The samples consist of endogenous samples from normal volunteers and patients, along with additional samples spiked with a highly purified source of human CRP to provide an extended clinical range used for the assessment of patients with ARI and COPD exacerbations. The programme assesses both site and method performance, including bias, within and between batch imprecision and linearity. Key Features: - Commutable, endogenous samples. - Samples targeted at appropriate thresholds for the management of patients with ARI and COPD exacerbations. - Programme assesses both site and method performance, including bias, within and between batch imprecision and linearity. - Scoring based on Milan Model 3 performance specification. For more information: https://www.weqas.com/services/poct-eqa/poct-crp/ or contact@weqas.com | ||||||
| Keywords | |||||||
| Product groups |
Health care / medical devices
|
||||||
| Testing fields |
Medical analysis
|
||||||
| Technical details | |||||||
|
|||||||
| Aims of the PT scheme | |||||||
| Target group of participants | The programme assesses both site and method performance, including bias, within and between batch imprecision and linearity. | ||||||
| Linked to specific legislation / standards | Accreditation by UKAS on the basis of ISO/IEC 17025, 17043 and 15195 | ||||||
| Additional, subsidiary aims | validation of testing methods | ||||||
| Number of participants | |||||||
| Accredited or otherwise reviewed by a 3rd party |
Accredited by UKAS on the basis of ISO/ IEC 17043 |
||||||
| Operation is commissioned / requested by | |||||||
| Fees and frequency | |||||||
| Participation fee | https://www.weqas.com/participantzone/subscription-charges/ | ||||||
| Regularly operated | Yes (Frequency: Bimonthly. Samples: 2 x 0.5mL. ) | ||||||
| Year of first operation | 2017 | ||||||
| Contact details of the PT provider | |||||||
| Provider | Contact person | ||||||
|
Weqas
Unit 6, Parc Ty Glas CF14 5DU Cardiff United Kingdom Phone: 44 (0) 2920 314750 Fax: Web: http://www.weqas.com http://www.weqas.com |
Laura Lloyd-Lewis
Phone: 44 (0) 29218 32884 Fax: Email: laura.lloyd-lewis@wales.nhs.uk laura.lloyd-lewis@wales.nhs.uk |
||||||
If you find any mistakes please contact the responsible EPTIS coordinator in United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.